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Differences in Cardiovascular Sensitivity to Propofol in a Chromosome 
Substitution Rat Model
Aim Based on previous observations of strain-related alterations in sensi-
tivity to anesthetics, this study used a newly established genetic rat model 
to identify differences in cardiovascular sensitivity to the commonly used, 
clinically relevant, anesthetic propofol and to correlate such differences 
with specific chromosomal substitutions.
Methods Cardiovascular sensitivity to propofol was compared in groups 
of normotensive Dahl Salt Sensitive (SS) and Brown Norway (BN) in-
bred rats, as well as in a unique panel of consomic rats based on these 
SS and BN parentals. The consomics were produced by introgression of 
individual BN chromosomes into an otherwise unchanged SS genetic 
background. Cardiovascular sensitivity was assessed by measuring the 
infusion rate of propofol required to reduce mean arterial blood pressure 
by 50% and cause cardiovascular collapse in each parental and consomic 
strain.
Results Significantly lower propofol infusion rates caused both a 50% 
reduction in mean arterial pressure and ultimate cardiovascular collapse 
in SS compared to BN. Substitution of BN chromosome 13, but not of 
any other BN chromosome, reversed the enhanced propofol sensitivity in 
SS rats to the level of BN rats.
Conclusions Differential propofol sensitivity exhibited by SS and BN 
rat strains is associated with chromosome 13. This is consistent with ear-
lier findings and represents the first complete screening of all rat auto-
somes for their relationship to anesthetic sensitivity. Initial localization 
of this sensitivity reversal to chromosome 13 provides a basis upon which 
additional, more selective genetic screening studies can be applied. Such 
studies may serve to identify specific regions of the genome responsible 
for different physiological responses to various anesthetic agents.
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All general anesthetics produce analgesia, al-
tered consciousness, and a general physiologic 
state that is favorable for the tolerance of pain-
ful stimuli. Despite decades of investigation, the 
wide diversity of effects that anesthetic agents 
have on cellular function has made it difficult to 
determine which of these effects are mechanisti-
cally significant for desired anesthetic action, ma-
jor side effects, or both. As basic science research 
has increasingly focused on potential genetic de-
terminants of cause and effect, research into the 
mechanisms and side effects of anesthetic action 
has likewise taken a similar turn. Since the ge-
netic code is ultimately responsible for the syn-
thesis of the receptors and other proteins that 
are thought to be modified by anesthetic agents, 
identifying genetic components associated with 
the sites and methods of anesthetic action is a 
promising endeavor. A genetically focused inves-
tigative schema may represent a way to accurately 
study anesthetic mechanisms while avoiding the 
confounding influence of superfluous effects on 
experimental systems (1).
We have previously demonstrated that Dahl 
Salt Sensitive rats (SS/JrHsdMcwi, abbreviat-
ed as SS) exhibit significantly greater cardiovas-
cular sensitivity to both volatile and parenteral 
anesthetics than do rats of the Brown Norway 
strain (BN/NhsdMcwi, abbreviated as BN), 
and further, that these sensitivity differences re-
main intact even when SS rats are normoten-
sive and maintained on a low salt diet (2,3). Our 
objective for the current study was to identify 
which regions of the rat genome are responsible 
for this cardiovascular sensitivity. For this task 
we employed a unique consomic methodology, 
which allowed us to investigate the effects of sin-
gle chromosome substitutions on cardiovascular 
sensitivity to anesthetic agents.
In this consomic model, single SS chromo-
somes were substituted with their BN equiva-
lents, while leaving the otherwise inbred parental 
genetic background unchanged (4). Once iden-
tified, any chromosome(s) associated with anes-
thetic sensitivity differences can be subdivided 
further, providing genetic insight into the mech-
anisms of anesthetic action. This strategy is be-
coming an increasing familiar model and is often 
referred to as functional genomics (5).
The hypothesis for this study is that there is 
an identifiable genetic basis which could explain 
the observed, strain specific differences in car-
diovascular sensitivity to the clinical anesthetic 
propofol, and that these observed sensitivity dif-
ferences result from genetically determined al-
terations in cardiovascular functions. If the genes 
involved in these sensitivity differences are lo-
calized to specific chromosomes, then selective 
chromosomal substitutions from BN rats to SS 
rats will reverse the anesthetic sensitive pheno-
type of the SS to the non-sensitive phenotype of 
the BN. In this way, we can identify candidates 
of interest for the ultimate identification and 
mapping of specific genes.
Methods
Experimental animals
The methodology for the present study was simi-
lar to that used previously (3), with some mod-
ifications. First, in addition to the parental ani-
mal strains SS and BN, consomic animal strains 
SS.1BN-SS.20BN were studied. This refers to the 
homozygous substitution of single BN chro-
mosomes, 1 through 20, into an otherwise un-
changed SS genetic background (4). Second, pro-
pofol, rather than a volatile anesthetic, was used 
as the experimental agent. All animals were pro-
duced from inbred parental strains, under the di-
rection of the Human and Molecular Genetics 
Center at the Medical College of Wisconsin.
Each consomic rat strain used in our study 
represented a single chromosome substitution. 
These consomic animals are a reliable and repro-
ducible model, bred from progenitors with dif-
fering anesthetic sensitivity profiles. The animals 
were developed over a 4-year period by conduct-
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ing a series of successive backcrosses. Genotyping 
was used to identify breeders from each genera-
tion, and crosses continued until the strain was 
homozygous at all loci. In this way, singly substi-
tuted animals representing all 20 SS autosomes 
and both sex chromosomes were developed (4). 
Once produced, SS.1BN-SS.20BN animals were 
maintained in a transgenic facility located with-
in the Medical College of Wisconsin’s Biological 
Resource Center, and were 8-12 weeks old when 
studied. A total of 93 animals were studied. All 
studies were approved by the Animal Care and 
Use Committee.
Animal preparation
During each experiment, spontaneously ventilat-
ing animals were anesthetized with 3% isoflurane 
and a tracheotomy was performed. Following 
tracheotomy placement, isoflurane was reduced 
to 2%, and both femoral arterial and femoral ve-
nous catheters were placed (6). Following cathe-
ter placement, the concentration of administered 
isoflurane was reduced to 0.5% and maintained 
until an attached infrared capnograph (Criticare 
POET 2, Critcare Systems Inc. Waukesha, WI, 
USA) indicated that end tidal isoflurane concen-
tration had decreased to 0.6%. At this point, in-
travenous propofol infusion was started at a rate 
of 550 µg kg-1 min-1 and isoflurane was discon-
tinued. The animal was then equilibrated for 10 
minutes or until the measured end tidal isoflu-
rane concentration reached 0.2%.
Propofol sensitivity measurements
The propofol infusion rate was initially increased 
by 30 µg kg-1 min-1 every 3 minutes, until the an-
imal no longer demonstrated extremity or tail 
movement in response to tactile stimulation. Fol-
lowing this loss of response, the sequential dose 
increase was raised from 30 µg kg-1 min-1 to 300 
µg kg-1 min-1, with each dose adjustment again 
separated by a 3-minute equilibration interval. 
The propofol infusion rate at which the mean ar-
terial blood pressure was reduced by 50% was re-
corded and then the sequential propofol dosage 
increases were raised to 3 mg kg-1 min-1. nfusion 
rate increases of 3 mg kg-1 min-1 were maintained 
until the point of cardiovascular collapse. Car-
diovascular collapse was defined as the time at 
which CO2 was no longer detectable on the end 
tidal medical gas analyzer and represented the 
cessation of all effective cardiac pumping.
Anesthetics and equipment
Throughout all experiments, inspired gas con-
sisted of a 30% O2/70% N2 mixture, which was 
used to reduce any possibility of hypoxia-in-
duced effects on the anesthetic responses. All of 
the animals were ventilated with a model 680 ro-
dent respirator (Harvard Apparatus Co., South 
Natick, MA, USA). Respiratory rate and tid-
al volumes were adjusted in such a way that end 
tidal CO2 was 35-40 mm Hg. End tidal CO2 and 
anesthetic concentrations were measured with 
a POET 2 infrared capnograph and end tidal 
agent monitor (Criticare Systems). Isoflurane 
was administered using an Ohio Medical Prod-
ucts vaporizer (Airco Inc., Madison, WI, USA). 
Propofol was purchased from Zenica Pharma-
ceuticals (Wilmington, DE, USA) and was in-
fused using a Harvard model 22-syringe infusion 
pump (Harvard Apparatus Co., South Natick, 
MA, USA).
Measurements and statistics
For each strain, the following two response 
points were of interest: mean dose of propofol re-
quired to reduce mean arterial blood pressure by 
50% and mean dose of propofol required to pro-
duce cardiovascular collapse.
Both mean infusion rate of propofol required 
to reduce mean arterial blood pressure by 50% 
and mean infusion rate of propofol required to 
produce cardiovascular collapse were determined 
for the SS and BN parental strains and for each of 
the 20 autosomally substituted consomic strains. 
These results were examined for any tendencies 
suggesting differential propofol sensitivity. The 
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BN parental group and the SS.13BN consomic 
were clearly less sensitive than the SS. Therefore, 
at least 10 studies for each of these three groups 
were completed. In contrast, there were no ten-
dencies toward differences between SS and any 
of the other consomics. Therefore, all of the re-
maining consomic data was pooled and analyzed 
in aggregate. The propofol infusion rates that re-
duced mean arterial blood pressure and the pro-
pofol infusion rates that produced cardiovascu-
lar collapse in SS, BN, SS.13BN and the pooled 
consomics were compared using analysis of vari-
ance and the Bonferroni post hoc test. We used 
Statistical Software for the Social Sciences, ver-
sion 11.0.4 for Macintosh computers (SPSS. Inc, 
Chicago, IL, USA), with a significance level of 
P≤0.05.
Results
Reduction in mean arterial blood pressure
Mean ± standard error of the mean (SEM) in-
fusion rate of propofol required to reduce mean 
arterial blood pressure by 50% was significant-
ly different between the two parental strains (SS 
and BN). In BN (n = 10) this rate was 3.4 ± 0.36 
mg kg-1 min-1, compared with a rate of 2.4 ± 0.18 
µg kg-1 min-1 in SS (n = 10). When compared to 
the parental strains, significant differences were 
also observed in the consomic groups. The infu-
sion rate of propofol required to reduce mean 
arterial pressure by 50% in the SS.13BN strain 
(n = 11) was 3.5 ± 0.36 µg kg-1 min-1. This was 
similar to the rate in BN and significantly dif-
ferent from that in SS (P≤0.001). In contrast, in 
all of the other consomic groups studied (n = 3-
5 for each chromosome 1-12, 14-20), the infu-
sion rate of propofol required to reduce mean 
blood pressure by 50% did not significantly dif-
fer from the SS. When pooled (ntotal = 62), this 
rate was 2.5 ± 0.35 µg kg-1 minute-1, represent-
ing a statistically significant deviation from BN 
and SS.13BN (P≤0.001) (Figure 1).
Cardiovascular collapse
When propofol infusions were increased to the 
point of cardiovascular collapse, observed strain 
differences followed the same pattern as was 
observed for 50% reduction in mean arterial 
blood pressure. The mean±SEM infusion rate 
of propofol that produced cardiovascular col-
lapse was 35 ± 1.2 mg kg-1 min-1 in SS, which 
was significantly less than the 49 ± 2.1 mg kg-
1 min-1 required to cause the same effect in BN 
(P≤0.001). Likewise, all of the consomics ex-
cept for the SS.13BN developed cardiovascular 
collapse at an infusion rate of propofol simi-
lar to the SS. Mean±SEM rate for this pooled 
Figure 1. Enhanced effect of IV administration of propofol in Dahl 
Salt Sensitive (SS) and pooled consomic strains (SS.1-20BN excluding 
13) vs Brown Norway (BN) and SS.13BN (n = 10, 62, 10 and 11, re-
spectively) in attenuating mean arterial blood pressure by 50%. Data 
shown are means±SEM of propofol infusion rates that attenuate mean 
arterial blood pressure by 50%. Asterisk indicates significant differ-
ence between BN and SS.13BN. There were no apparent differences 
between any of the other consomic strains and SS.
Figure 2. Earlier cardiovascular collapse in Dahl Salt Sensitive (SS) 
and consomic Strains (SS.1-20BN excluding 13) vs Brown Norway (BN) 
and SS.13BN (n = 10, 62, 10 and 11, respectively) in response to IV 
administration of propofol. Data shown are means±SEM of propofol 
doses that produce cardiovascular collapse. Asterisk indicates sig-
nificant difference between BN and SS.13BN. There were no apparent 
differences between any of the other consomic strains and SS.
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group was 32 ± 0.8 mg kg-1 min-1. In contrast, 
in SS.13BN this rate was 49 ± 2.5 mg kg-1 min-
1, which was similar to BN and significantly 
greater than both the SS and the pooled conso-
mics (Figure 2).
Discussion
The results of the present study demonstrate that 
SS rats exhibited greater cardiovascular sensitiv-
ity to propofol than BN rats. It further demon-
strates that this increased sensitivity can be re-
versed by substituting BN chromosome 13 into 
an otherwise genotypically intact SS background. 
The fact that this reversal is not observed in any 
of the other consomic strains strongly suggests 
that the genetic factors responsible for these sen-
sitivity differences are associated with chromo-
some 13.
Although consomic methodology is a rela-
tively new approach (4), the study of a genet-
ic basis for differences in anesthetic sensitivity 
has been an area of interest for many years. Over 
thirty years ago, the first evidence of a genet-
ic basis for altered anesthetic sensitivity was re-
ported with the identification of an ether-resis-
tant strain of Drosophila. Since that time, a large 
number of mutations in this species correlating 
with enhanced or reduced sensitivity to differ-
ent anesthetics have been identified (7). More 
recently, naturally occurring differences in mea-
sured minimum alveolar concentration (MAC) 
values of halothane, isoflurane, and desflurane 
between different stains of mice have been iden-
tified (8). Similarly, a specific quantitative trait 
locus (QTL) accounting for the observed differ-
ences in emergence times from propofol injec-
tions in mice has been identified and mapped (9). 
A similar genetic approach has also been used to 
successfully demonstrate that in vivo differenc-
es in vasoreactivity during cardiopulmonary by-
pass in human correlates with polymorphism of 
the angiotensin converting enzyme gene (10). 
Novel use of knockout genes in mice has demon-
strated a difference in anesthetic sensitivity, com-
pared with control, linked to the GABAA recep-
tor (11). Finally, in the soil nematode C. elegans, 
a number of mutations associated with altered 
anesthetic sensitivity have been identified and 
mapped via cross breeding followed by positional 
cloning of QTLs (12).
The chromosomal substitution technique in 
the present study represents a powerful alterna-
tive to either extensive screening studies of ex-
isting strains or the development of new strains 
via phenotypically selective inbreeding (13). 
Even though a single consomic strain can only 
be used to study the effects of a single chromo-
somal substitution, an entire consomic panel, by 
design, greatly facilitates the study of potential-
ly multifactorial traits. Multifactorial traits are 
much more common than single gene traits, but 
their biologic complexity makes them difficult to 
study with traditional knockout or ethyl nitro-
sourea mutagenesis methodologies.
Perhaps the greatest strength of the present 
consomic model is the fact that SS and BN pa-
rental strains are inbred, and should thus be, ge-
netically identical. Hence, as a result of this in-
breeding in the parental strains, the consomic 
animals have isogenic backgrounds. In models 
that do not utilize inbred parental strains, it is 
difficult to distinguish whether an observed dif-
ference in response to an anesthetic is truly a dif-
ferential gene/chromosome effect or is simply a 
result of background heterogenicity. Heteroge-
nicity which may, in fact, modulate anesthetic 
response in some unidentified fashion. In con-
trast, within the context of our consomic model, 
the SS parental strain represents a “true control” 
for the SS.13BN. This is because any differences 
in anesthetic sensitivity are necessarily related to 
mechanisms associated only with the chromo-
somal substitution, since the remainder of the 
genetic background is isogenic. In a sense, this 
model is analogous to comparing single chromo-
somal substitution effects in inbred animals vs 
outbred animals – ie, identical vs non-identical 
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twins. In this way, the complexity of significant 
background allelic variation is eliminated.
The results of the present study establish a 
correlation between the observed anesthetic sen-
sitivity and chromosome 13. Although our re-
sults do not completely exclude the possibility 
that other influential chromosomes will be iden-
tified, the fact that we did not detect any such 
chromosomes in our survey of the full consomic 
panel suggests that this is unlikely. However, one 
issue which does need clarification is the possi-
bility that the enhanced sensitivity of the SS was 
somehow related to the development of salt sen-
sitive hypertension. We attempted to control for 
this possibility by maintaining all of the studied 
animals on low salt diets (0.4% NaCl). This diet 
has been shown to delay the development of hy-
pertension in salt sensitive animals beyond the 8-
12 week age range that we used (14). Moreover, 
in preliminary data, we observed no significant 
differences in pooled baseline mean arterial pres-
sures between SS, BN, SS.13BN and representative 
consomic animals (142 ± 16, 133 ± 21, 139 ± 18, 
and 137 ± 14 mm Hg, respectively). According-
ly, anesthetic sensitivity and mean arterial pres-
sure appear to be unrelated in this animal model. 
In our present study, we demonstrate that sub-
stitution of BN chromosome 13 into the SS iso-
genic background produces a reversal of SS asso-
ciated anesthetic sensitivity, but substitution of 
any other BN chromosome into the SS isogenic 
background does not. Thus, only the SS.13BN an-
imals demonstrate an anesthetic sensitivity pro-
file similar to the BN parentals, whereas all other 
consomics demonstrate an anesthetic sensitivity 
profile similar to the SS.
Alone, our current results do not explain the 
mechanistic links between chromosome 13 and 
propofol sensitivity. However, the application of 
our methodology to a unique class of anesthetic 
agents, as represented by the current study, is an 
interesting and necessary step toward elucidating 
mechanistic detail. Given that our methodology 
has now been applied to different classes of anes-
thetic compounds with similar results, the cur-
rent study serves to generalize the observed sensi-
tivity differences across the borders of drug class, 
and to narrow the potential field of mechanistic 
possibilities. For example, a class specific or drug 
specific response would tend to suggest a specif-
ic receptor alteration or a modification of a drug 
metabolism pathway. In contrast, the observed 
similarity in cardiovascular response across drug 
class is more likely to suggest an underlying phys-
iological difference such as altered sympathetic 
tone or ion channel density.
Although it is tempting to propose that a 
common mechanism related to chromosome 13 
is involved in both 50% MAP reduction and in 
total cardiovascular collapse, and that total car-
diovascular collapse represents a progression of 
earlier blood pressure changes, this cannot be 
supported without additional data. However, 
as more correlation between genotype and phe-
notype becomes available from sources such as 
the National Institutes of Health-sponsored Rat 
Genome Project (15), investigators will gain the 
ability to correlate traits localized to chromo-
somes, or portions of chromosomes, with known 
markers. Similarly, because our consomic ani-
mals have inbred genomic backgrounds, chro-
mosomes of interest can be subdivided further 
by developing congenic substrains on the same 
genomic background. By separating whole chro-
mosomes into smaller substitutions, the congen-
ic approach allows for further characterization 
and localization of the genetic basis for complex 
genotypic traits. It is hoped that data such as ours 
will eventually contribute to a greater under-
standing of anesthetic sensitivity in humans.
This understanding will progress if known 
linkages in rats can be compared with existing li-
braries of sequences already known from the hu-
man and mouse genome projects. Thus, these 
results provide the basis upon which we can ap-
ply additional and more selective genetic screen-
ing studies in order to identify the regions of the 
rat genome responsible for different responses 
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to various anesthetic agents. Characterization of 
these differences, on both a phenotypic and ge-
notypic level, will contribute to an enhanced un-
derstanding of the coupling between the mech-
anisms of anesthetic action on vascular smooth 
muscle and overall cardiac stability during an-
esthesia. Such an understanding is important in 
developing improved anesthetic techniques, par-
ticularly for individuals with demonstrated sensi-
tivity to anesthetic agents.
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